) announced that it will participate at the Annual Meeting &
Exposition of the Controlled Release Society (CRS) in Chicago,
Ill., for a poster session entitled "Predictive Modeling and
Validation of Tamoxifen Release from Ethylene Vinyl Acetate (EVA)
Copolymers" to be presented on Jul 13.
Celanese EVA Performance Polymers can help pharmaceutical companies
develop novel, controlled release products based on its EVA
polymers. EVA excipients boast unique performance properties that
offer pharmaceutical manufacturers new product possibilities.
Celanese's VitalDose Ethylene Vinyl Acetate (EVA)-based excipients
deliver the reliable performance required for pharma and medical
device applications. EVA is an easy to process material and the
VitalDose brand represents a commitment to each of its customers to
help them realize their product objectives. The study demonstrates
the versatility of VitalDose EVA, offering predictively-modeled
dosage of the main oncology drug Tamoxifen.
EVA was assessed in the study with selected active
pharmaceutical ingredients (APIs). The API solubility and release
profiles were studied using Hansen Solubility Parameter
calculations and experimental in vitro elution. The study showed a
method that can be used for initial formulation design for
controlled drug delivery from EVA copolymers.
Celanese posted better-than-expected first-quarter 2014 results on
Apr 21. Both revenues and adjusted earnings for the quarter topped
the Zacks Consensus Estimate.
Celanese holds a Zacks Rank #2 (Buy).
Other companies in the chemical space worth considering include
KMG Chemicals Inc.
Minerals Technologies Inc.
) While KMG Chemicals and Minerals Technologies sport a Zacks Rank
#1 (Strong Buy), Ashland holds a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
CELANESE CP-A (CE): Free Stock Analysis Report
KMG CHEMICALS (KMG): Free Stock Analysis Report
ASHLAND INC (ASH): Free Stock Analysis Report
MINERAL TECH (MTX): Free Stock Analysis Report
To read this article on Zacks.com click here.